

COMy 2022 Preliminary Scientific Program
All program timing in CEST

Day 1, Thursday, May 12th	
09:00-10:15	Pre-congress industry or non-profit satellite symposium
10:15-10:30	COMy 2022 kick-off: welcome by Congress chairs
10:30-12:00	Session 1: How to assess disease risk?
10:30-10:45	Diagnostic criteria and state of the art work-up Shaji Kumar, USA
10:45-11:00	What is standard risk, high risk and ultra-high risk ? Hervé Avet-Loiseau, France
11:00-11:15	The role of the transcriptome TBA
11:15-11:30	The role of imaging Elena Zamagni, Italy
11:30-11:45	Role of precursor conditions Irene Ghobrial, USA
11:45-12:00	Round table discussion <i>Speakers and moderators</i>
12:00-12:15	Break
12:15-13:15	Industry lunch symposium
13:15-13:30	Break
13:30-15:00	Session 2: Mechanisms of resistance in myeloma
13:30-13:45	Resistance to IMiDs TBA
13:45-14:00	Resistance to proteasome inhibitors TBA
14:00-14:15	Resistance to antibodies Niels van de Donk, The Netherlands
14:15-14:30	Resistance to immune therapies Paola Neri, Canada
14:30-14:45	Defining disease aggressiveness during therapy Gareth Morgan, USA
14:45-15:00	Round table discussion <i>Speakers and moderators</i>
15:00-15:15	Break
15:15-16:45	Session 3: Frontline therapy of transplant eligible patients
15:15-15:30	Overview of induction regimens Philippe Moreau, France
15:30-15:45	Role of consolidation (including double auto-transplant) Michele Cavo, Italy
15:45-16:00	Maintenance approaches post-transplant Marivi Mateos, Spain
16:00-16:15	Special approaches in high-risk cytogenetics Peter Sonneveld, The Netherland
16:15-16:30	Round table discussion <i>Speakers and moderators</i>
16:30-16:45	Break
16:45-18:15	Industry symposium
18:15-18:30	Break
18:30-19:45	Session 4: Plenary lectures
18:30-18:50	Advances in AL amyloidosis Giampaolo Merlini, Italy
18:50-19:10	Advances in Waldenström macroglobulinemia Steve Treon, USA
19:10-19:30	Epidemiology of plasma cell dyscrasias Sigurdur Kristinsson, Iceland
19:30-19:45	Q & A
19:45-20:00	Break
20:00-21:30	Industry symposium

Day 2, Friday, May 13th	
08:30-09:00	Session 5: How do I manage?
09:00-10:00	Session 6: The IFM session
10:00-11:15	Session 7: Updates from the recent frontline clinical trials
10:00-10:10	OPTIMUM/MUK9 TBA
10:10-10:20	CONCEPT TBA
10:20-10:30	GRIFFIN TBA
10:30-10:40	FORTE Francesca Gay, Italy
10:40-10:50	MASTER Luciano Costa, USA
10:50-11:00	GMMG-HD7 TBA
11:00-11:15	Q&A
11:15-11:30	Break
11:30-12:45	Session 8: Treatment of non-transplant eligible patients
11:30-11:45	Frailty assessment TBA
11:45-12:00	Standard of care therapy Thierry Facon, France
12:00-12:15	Treatment of the ultra-frail patients TBA
12:15-12:30	The patient perspective TBA
12:30-12:45	Round table discussion <i>Speakers and moderators</i>
12:45-13:00	Break
13:00-14:00	Industry lunch symposium
14:00-14:15	Break
14:15-16:15	Session 9: Management of special clinical situations
14:15-14:30	COVID-19 vaccination in myeloma: where do we stand? Heinz Ludwig, Austria
14:30-14:45	Practical considerations when using anti-CD38 antibodies Torben Plesner, Denmark
14:45-15:00	Management of renal impairment TBA
15:00-15:15	Infection prophylaxis TBA
15:15-15:30	Cardiac complications Michel Delforge, Belgium
15:30-15:45	Guidelines for the use of bisphosphonates TBA
15:45-16:00	Round table discussion <i>Speakers and moderators</i>
16:00-16:15	Break
16:15-17:45	Industry symposium
17:45-18:00	Break
18:00-19:30	Session 10: Plenary lectures
18:00-18:20	Genomics of myeloma: what's new? TBA
18:20-18:40	MGUS: diagnosis, risk stratification and management TBA
18:40-19:00	MRD evaluation: How, When and for which goal? Jesus San Miguel, Spain
19:00-19:15	Q & A
19:15-19:30	Awards Ceremony
19:30-19:45	Break
19:45-21:15	Industry symposium

Day 3, Saturday, May 14 th	
08:30-09:00	Session 11: How do I manage?
09:00-10:00	Session 12: The IMS session
10:00-11:15	Session 13: Hot debates
10:00-10:25	MRD to drive therapy Pro Bruno Paiva , Spain Con TBA Discussion
10:25-10:50	Immune therapies replacing ASCT frontline Pro TBA Con Arnon Nagler , Israel Discussion
10:50-11:05	Break
11:05-12:35	Session 14: Novel agents for relapse: the latest data about:
11:05-11:15	Antibodies and proteasome inhibitors combinations for first relapse TBA
11:15-11:25	Antibodies and IMiDs combinations for first relapse TBA
11:25-11:35	CelModis Sagar Lonial , USA
11:35-11:45	XPO inhibitors Nizar Bahlis , Canada
11:45-11:55	Manipulation of apoptotic pathways Cyrille Touzeau , France
11:55-12:05	HDAC inhibitors Enric Ocio , Spain
12:05-12:15	Antibody-drug conjugates TBA
12:15-12:35	Round table discussion <i>Speakers and moderators</i>
12:35-12:50	Break
12:50-13:50	Industry lunch symposium
13:50-14:05	Break
14:05-15:35	Session 15: Immune therapy in relapsed/refractory myeloma
14:05-14:20	CAR T cells Noopur Raje , USA
14:20-14:35	Bi-specific antibodies TBA
14:35-14:50	Management of CRS and neurotoxicity Salomon Manier , France
14:50-15:05	Integrating immune therapies and autologous transplantation Hermann Einsele , Germany
15:05-15:20	Immune therapies at first relapse: pro and con TBA
15:20-15:35	Round table discussion <i>Speakers and moderators</i>
15:35-15:50	Break
15:50-16:50	Industry symposium
16:50-17:05	Break
17:05-18:05	Session 16: Plenary lectures
17:05-17:25	Therapy at first relapse: current data and perspectives TBA
17:25-17:45	The requirements for operational cure Jean-Luc Harousseau , France
17:45-18:05	Round table discussion <i>Speakers and moderators</i>
18:05-18:35	Session 17: Plenary closing lecture
18:05-18:35	Multiple myeloma cured in 2030: what are the next steps? Kenneth Anderson , USA
18:35	Meeting conclusions and adjourn